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Abstract 
Dementia with Lewy bodies and Parkinson’s disease dementia, jointly known as Lewy body dementia 
(LBD), are common neurodegenerative conditions. Patients with LBD present with a wide range of 
cognitive, neuropsychiatric, sleep, motor, and autonomic symptoms. The expression of these varies 
between individual patients, and over time. Treatments may benefit one symptom, but at the 
expense of worsening another, making management difficult. Often symptoms are managed in 
isolation and by different specialists, which undermines high quality care.   
 
Clinical trials and meta-analyses now provide an improved evidence base for the treatment of 
cognitive, neuropsychiatric and motor symptoms in LBD, in addition to which expert consensus 
opinion supports the application of treatments from related conditions such as Parkinson’s disease 
(PD) for the management of, for example, autonomic symptoms. There remain however clear 
evidence gaps and there is a high need for future clinical trials focused on specific symptoms in LBD. 
 
Introduction 
Lewy body dementia (LBD), a term which comprises both dementia with Lewy bodies (DLB) and 
Parkinson’s disease dementia (PDD), represents the second most common cause of 
neurodegenerative dementia.1-3 DLB accounts for 4.2-7.5% of cases of dementia in clinic-based 
studies1,2, and PDD is a frequent outcome for patients with PD, with up to 80% of patients affected in 
the long term.4 Consensus clinical diagnostic criteria have been proposed for both DLB3 and PDD,5 
and the relationship between the two disorders remains to be clarified. They likely represent 
different points along a Lewy body disease continuum with pathological and genetic overlap6,7 and 
currently are demarcated clinically from one another using the “one-year rule”, based on the 
temporal onset of motor relative to cognitive symptoms.3  
 
DLB and PDD are complex and heterogeneous disorders; patients present with a wide range of 
cognitive, neuropsychiatric, sleep, motor and autonomic symptoms.3,5 There have been guidelines 
outlining some treatment options for DLB and PDD (e.g.8-10), but there is no comprehensive guide to 
management. Treatment of LBD has particular challenges. Symptoms are expressed variably 
between patients and over time, natural fluctuations in symptoms are an inherent part of the 
disease, and frequently treatment of one symptom can worsen another.  Furthermore, an individual 
patient’s symptoms are often managed by different specialists, leading to uncoordinated and 
suboptimal care.11,12 With the inclusion of DLB and PDD in DSM-5 and ICD-11 and the development 
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of diagnostic toolkits to improve case detection13 there is a clear need for an inclusive, and 
standardised, management approach for LBD to improve care and outcomes.   
 
Up to now, the evidence base for treatments in LBD has been limited. However, additional trials now 
allow for robust systematic and meta-analytic reviews of the evidence.14-18, and there is  new 
evidence, for example, for the treatment for symptoms such as  parkinsonism19 and daytime 
somnolence.20. Thus a review focussed on the clinical management of LBD is timely and appropriate.  
 
There remain some gaps, for example, there are few data focussed on how to manage autonomic 
and sleep symptoms in LBD. These non-motor symptoms are evident in advanced PD and therefore 
drawing upon the wider evidence base in PD to inform best practice in LBD is appropriate. Similarly 
there is more interventional trial data in AD for cognitive and neuropsychiatric symptoms. In this 
review, to address these gaps, we include independent opinion developed from a Delphi consensus 
process (described in detail in Appendix) drawing upon expert clinical experience and data from 
related disorders such as AD and PD. We focus on the progress made in bringing these elements 
together to provide a basis for a comprehensive management approach to LBD and present our 
management review in a problem orientated format, covering the key symptom domains of 
cognitive impairment, neuropsychiatric symptoms, motor features before moving to  autonomic and 
sleep symptoms, which have often been neglected previously and identify key evidence gaps and 
areas for future consideration including suggestions of future treatment trials for specific symptoms.  
 
Cognitive Impairment 
Attention, executive and visuo-perceptual abilities are disproportionately affected in LBD compared 
to naming and memory3, with variations in cognitive function (cognitive fluctuation) a key feature 
and a core symptom for DLB diagnosis.3 Systematic reviews and meta-analyses found that the 
cholinesterase inhibitors (ChEI) donepezil (6 trials in both 15 and 14) and rivastigmine (5 trials in 15 and 
2 in 14) were similarly effective in both DLB and PDD for improving cognition. Positive impacts on 
activities of daily living and caregiver burden were also found. One meta-analysis15 suggested 
rivastigmine was also associated with reduced mortality in LBD, although this effect disappeared 
with a trial sequential analysis. Both drugs are recommended as first line treatment in DLB by the 
United Kingdom National Institute for Health and Care Excellence.10 Donepezil is licensed for the 
treatment of DLB in Japan, and rivastigmine for PDD in the USA and some European countries. 
Evidence of the efficacy of galantamine in LBD is sparse as there are only open-label trials supporting 
its use and these are of lower quality.14,15  
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Typically the choice of ChEI is influenced by ease of administration, side effect profile, presence of 
comorbidities, dose titration regime, cost, care-giver preference and previous clinical experience.21 
Rivastigmine may be associated with more adverse events in both PDD and DLB than donepezil 14,15  
although has a transdermal patch formulation which, in PDD, appears to have less gastrointestinal 
side effects than oral rivastigmine.22 An open-label study of seven patients with LBD supported the 
benefit of high-dose ChEIs23 although this was at the cost of increased side effects. An absence of 
improvement should not be a reason for discontinuation of ChEIs, as patients with LBD are less likely 
to deteriorate whilst taking them.14 There are no controlled trials of ChEI withdrawal, though an 
open-label trial of 19 LBD patients found that sudden withdrawal may be associated with 
deterioration in both cognition and neuropsychiatric symptoms.24  
 
Studies of memantine show that it is well tolerated in LBD, but evidence for efficacy remains 
mixed.14,15  Two major 24-week, double-blind, randomised control trials25,26 which included both DLB 
and PDD patients (271 patients in total) reported significant overall clinical global impression of 
change (CGI-C) improvements 14. However there was no consistency between studies in terms of 
which symptoms improved or whether DLB or PDD sub-groups benefited more from the drug.14  
Posthoc analyses of data from 51 patients in one study 25 found the improvement in CGI-C scores 
was related to improvements in attention.27 Other posthoc analyses from this trial and others have 
reported improvements in patient quality of life and a reduction in care-giver burden.28,29 A 36 
month open label, follow-up study of  42 patients from one centres in one of the memantine 
studies25 suggested that a positive response to memantine was associated with improved survival in 
LBD although the small sample size may have introduced biases and precluded analysis of any 
covariates.30 Dosing, side effects and the use of different ChEI and memantine in LBD are described 
in table 1. 
 
In summary, there is good evidence for the efficacy of rivastigmine and donepezil in LBD, but better 
controlled studies of galantamine are needed to draw conclusions about this agent. Memantine may 
have some benefits, but further studies with larger numbers of DLB and PPD subjects are needed. It 
is also unclear whether memantine should be used as a monotherapy or whether it should be 
combined with ChEI, as only one of the two trials of memantine allowed concomitant ChEI use.25  
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Neuropsychiatric symptoms 
Patients with LBD present with a variety of neuropsychiatric symptoms, including visual 
hallucinations, hallucinations in other modalities, systematised delusions, apathy, aggression, 
anxiety and depression.31 Symptoms may not always need treatment, for  example, hallucinations 
may be regarded neutrally, or as comforting or pleasurable, and have limited or no impact on 
psychosocial function.3,32 Patients frequently lack insight or awareness into the extent of their 
neuropsychiatric symptoms, so including informant information in the clinical assessment is 
essential. Rating scales, e.g. for visual hallucinations33, can provide a useful framework for assessing 
severity and frequency of symptoms and monitoring treatment response.  Scales can either be 
specific to a symptom or composite; the latter which aggregate several symptoms, such as the 
Neuropsychiatric Inventory,34 have tended to be used as measures in clinical trials in LBD 
(e.g.25,26,35,36).  
 
As for other dementias, non-pharmacological interventions are usually advocated as  first line 
treatment for neuropsychiatric symptoms,10 though the evidence base for these in LBD is limited, 
with very few randomised controlled trials.17,18 In this context, application of approaches shown to 
be effective in AD may also be helpful in LBD, although there is no specific consensus as to if or how 
they may be adapted.18 Electroceutical approaches are increasingly being investigated in LBD; 
improvements in depression have been reported with electroconvulsive therapy in DLB in a number 
of case series (22 patients in total)18 and one case series of six DLB patients suggested rapid rate 
transcranial magnetic stimulation reduced depression scores significantly.37 In contrast, randomised 
sham-control trials of transcranial direct current stimulation in LBD have not shown benefits  for 
cognitive remediation (42 patients)38 or hallucinations (36 patients).39 There is preliminary evidence 
suggesting that DBS (deep brain stimulation) to the nucleus basalis of Meynert in 6 PDD patients 
may improve neuropsychiatric outcomes 40 and this warrants further investigation. 
 
If symptoms are severe or distressing, or non-pharmacological measures have failed, then 
pharmacotherapy may be indicated.10 Studies of donepezil and rivastigmine have found 
improvements in composite scores of neuropsychiatric symptoms in LBD.15 although identifying 
specific symptom benefit is more challenging, as these are not frequently reported in studies. Scores 
which aggregate apathy, delusions, depression and hallucinations have indicated a benefit in DLB 
from donepezil but not rivastigmine.35,36 One systematic review14 suggested that donepezil, but not 
rivastigmine, may have specific benefits for delusions, hallucinations and cognitive fluctuations in 
DLB. Conversely in PDD, donepezil does not appear beneficial for hallucinations, hostility, 
6 
 
suspiciousness or unusual thought content.41 Interpretation is difficult, but considering findings 
collectively, expert opinion from our Delphi  consensus group as well as national guideline bodies 
(e.g.10)  have endorsed the use of rivastigmine and donepezil for neuropsychiatric symptoms. Open-
label trial data of galantamine provides tentative evidence of improved cognitive fluctuation, sleep 
and psychiatric symptoms in DLB42; and hallucinations, anxiety, apathy and sleep symptoms in PDD43 
and thus could be an alternative if other ChEIs aren’t tolerated. There is no consistent evidence of a 
clear or significant effect of memantine on neuropsychiatric symptoms in LBD.14,15 
 
If psychotic symptoms remain problematic despite ChEI or memantine treatment, then a trial of an 
antipsychotic agent may need to be considered although this needs to be balanced against a scarcity 
of documented efficacy of these agents when assessed systematically14 and the high risk (up to 50%) 
of  severe sensitivity reactions with antipsychotics in LBD which can be life-threatening and a longer 
term elevated mortality risk44-46 If prescribed in LBD, there needs to be a high degree of caution in 
their use.47  There is no evidence to favour any one anti-psychotic drug in LBD. Quetiapine appears 
to have the least side effects although evidence for its efficacy in PD9 and LBD is insufficient.14 
Clozapine, effective in PD psychosis48 may also help in LBD, although again specific trials for use of 
this agent in the latter are absent.  Pimavanserin, a new antipsychotic with specific inverse agonism 
at the 5HT2A receptor, and available in US although not Europe, has demonstrable antipsychotic 
properties in PD psychosis;49 its efficacy and safety remain to be formally evaluated in LBD. 
 
Depression occurs in about one third of LBD patients50,51 and is often accompanied by anxiety. 
Pharmacological treatments for depression and anxiety in LBD have not been adequately evaluated, 
with the highest level of evidence from a small randomised control trial of citalopram in 14 DLB 
patients which failed to demonstrate efficacy and found high levels of adverse effects.52 Higher 
quality trial evidence exists for venlafaxine, a selective serotonin norepinephrine reuptake inhibitor 
(SNRI) in PD whereas data for selective serotonin reuptake inhibitors (SSRIs) and tricyclics are less 
conclusive.9 Given the sensitivity of LBD patients to anticholinergic side effects the expert consensus 
view is that antidepressants known to have these effects are best avoided.  
 
In summary, there is a dearth of studies of non-pharmacological management of neuropsychiatric 
symptoms in LBD and more are needed. ChEI may help, but further studies focussing on which 
particular symptom domains are most likely to improve are needed. The impact of memantine on 
neuropsychiatric symptoms needs to be examined in large controlled studies. Studies of 
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pimavanserin in LBD for psychosis, and controlled trials of antidepressants for depression, are 
needed.  
 
Motor Symptoms  
Up to 85% of DLB subjects experience motor difficulties3 although rest tremor is less prevalent than 
in PD53 and motor symptoms may be less treatment-responsive in DLB.54 In contrast, in PDD 
parkinsonism can be moderate to severe and patients have often been exposed to long-term and 
high-dose antiparkinsonian medications with commensurate side effects including motor 
fluctuations and psychosis.55,56 Thus the management of motor symptoms can differ markedly 
between DLB and PDD (table 2).  
 
There have been no double-blind controlled trials of  levodopa therapy in DLB, or of whether 
changing to a levodopa monotherapy regime in PDD is beneficial. However, open-label studies 
suggest that both acute and chronic levodopa monotherapy use can help motor function and reduce 
tremor in DLB and PDD.54,57 Improvements  in motor function appear greater in PDD than DLB (65-
70% vs. 32-50%)14 and in the latter  approximately one in three levodopa treated patients will 
experience psychotic symptoms.57 A meta-analysis of four double-blind randomised controlled trials 
in 1,068 PD patients,58 and a Phase II trial in 158 early stage DLB patients, have reported a motor 
improvement with zonisamide, an anti-epileptic agent, when used as adjunctive treatment to 
levodopa.19 
 
In terms of non-pharmacological approaches, DBS is an effective treatment for motor symptoms in 
selected PD patients. 59. However pre-existing cognitive impairment is a contraindication and DBS, in 
itself, may subtly impair cognitive function.60   
 
In summary, open label studies show some motor benefit for levodopa therapy in LBD, so this can be 
used for motor symptoms, though adverse effects including psychosis may occur in up to third. 
Further double-blind studies are indicated, both of levodopa and also newer agents like zonisamide. 
 
Falls 
Falls are common in LBD and associated with significant morbidity and mortality.61,62 Contributors to 
fall risk in LBD are typically multifactorial including parkinsonism, dysautonomia, and frailty.62 
Physiotherapy has a clear evidence base in PD and can help improve balance, power and flexibility, 
as well as enhance mobility, all factors which can decrease the risk of falls and improve functional 
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independence.62,63 Unfortunately, there  is no evidence specifically in LBD, and studies are needed 
especially as cognitive impairment and other comorbid symptoms could adversely influence 
engagement with therapy.  
 
Autonomic dysfunction 
There are a wide range of autonomic symptoms in LBD, and these are associated with more rapid 
disease progression and shorter survival.64 Despite the prominence and impact of these symptoms, 
there is no established evidence base for their treatment in LBD so opinion on best management is 
largely drawn upon the more established evidence base in PD.8,65,66 
 
Orthostatic hypotension 
Fludrocortisone and midodrine have been suggested as useful in PD8,9,67 although there are no LBD 
data and only limited data in PD (See table 3), and both agents require specific monitoring with the 
availability of midodrine being restricted in some countries. Droxidopa is licensed in some countries 
(e.g. United States) for orthostatic hypotension in PD. Whilst no data exist in LBD, given its low side 
effect profile68 use of droxidopa in LBD may be an option where available. Further details on these 
drugs are described in table 3. The importance of treating orthostatic hypotension in LBD is 
highlighted by the link between orthostatic hypotension and attention-executive impairments in PD 
raising the possibility that treatment of the former may have benefits beyond the hypotension in 
itself, and controlled trials are needed to assess this.69  
 
Gastrointestinal dysfunction 
The full extent of the alimentary tract can be affected in LBD with symptoms ranging from 
sialorrhoea to dysphagia, gastroparesis and constipation.70,71  In PD the prevalence of excessive 
drooling has been reported in controlled studies to range from 10 to 81% with significant negative 
impacts on quality of life and social and emotional function.72 Drooling may be related to inefficient 
swallowing which leads to high rates of aspiration (>80%) in LBD.73 A randomised control trial 
exploring interventions to prevent aspiration including 132 PDD with dysphagia found lower rates of 
aspiration as evidenced on videofluoroscopy, with honey thickened fluids (59% compared to 64-69% 
with other interventions)74.  Another study noted improved swallowing function objectively in 48 
LBD patients referred for videofluoroscopy with carbonated liquids.73 Whether such interventions 
have clinically meaningful impacts (e.g. prevention of aspiration pneumonia) remains to be resolved. 
A randomised cross-over trial of glycopyrrolate (1 mg, twice or three times a day) in 23 PD patients 
found that 9 of patients had a clinically relevant improvement in sialorrhea 75 over a four week 
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period; however the efficacy of this agent in LBD is not known. An evidence based review of 
botulium toxin injection to the salivary glands appears effective and safe in PD72, and thus by 
extension in LBD, though repeated injections are needed.  
 
Gastric emptying appears even slower in DLB than in PD76 and correlates with severity of motor 
impairment.77 Impairments in gastric motility can lead to fullness, reflux and excess eructation and 
importantly impact on drug absorption. Management includes avoidance of high fat foods, drinking 
during meals as well as walking after meals plus an awareness that dopaminergic medications can 
exacerbate gastroparesis.70,78  Domperidone, a peripheral dopamine blocker may have efficacy in the 
treatment of gastroparesis in PD78,79 but there are significant concerns with regard to cardiotoxicity 
and the risk of QT prolongation so it is not available in all countries, e.g. not in the United States.  
 
Constipation is one of the most common symptoms in LBD.80 Prolonged colon transit time and pelvic 
floor dyssynergia have been implicated as causes70,71. Constipation can also be exacerbated by 
opiates and anticholinergics,80,81 poor fluid intake, reduced fibre intake and sedentary behaviour. 
Polyethylene glycol (macrogrol) and psyllium increase bowel frequency in PD82,83 and along with 
dietary modification, increased fluid intake and suppositories are advocated as treatments for 
constipation in LBD (expert opinion). Stronger laxatives, suppositories or enemas may be needed in 
severely affected patients.66 Lubiprostone, a bicyclic fatty acid which activates type-2 chloride 
channels (ClC-2) in the gut and enhances intestinal secretions has been shown to have short term 
benefits in PD.80,84  
 
In summary, controlled trial evidence supports the use of thickened liquids to reduce aspiration in 
LBD, but studies of interventions to help other symptoms such as constipation are needed. Until 
then, the evidence-base for PD can be used to inform management of gastrointestinal symptoms in 
LBD.   
 
Urinary symptoms 
Urinary symptoms in LBD are very common and include urgency, frequency and incontinence.85 
Despite this, there are no LBD specific trials with data coming instead from PD. In this context, a 
double blind randomised controlled trial of solifenacin over 12 weeks in 23 PD patients with urinary 
frequency, incontinence and nocturia reported significant reduction in micturition frequency.86 
However anti-muscarinics (including solifenacin) have high levels of adverse effects including 
cognitive87 which may be a contraindication for their use in LBD. An alternative drug without 
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cognitive side effects is mirabegron, a beta 3-adrenoceptor agonist; a retrospective cohort study 
which considered 50 patients between 2012 and 2017 suggested this agent was well tolerated in PD 
and offered benefit.88  
 
Excess sweating 
Hyperhidrosis is reported by two thirds of PD patients,89 is associated with disease severity and may 
be associated with motor fluctuations90,91 although how common it is in LBD is not known. It has 
significant social and emotional impacts and may occur with other autonomic disturbances.89 There 
are no treatment trials but there was a consensus from our  Delphi panel group that patients may 
benefit from the use of loose fitting clothing, cotton bedding for night sweats and antiperspirants as 
well as avoidance of triggers e.g. alcohol, spicy foods, hot rooms. For those with dyskinesias and 
hyperhidrosis, reducing dopaminergic medication should be considered.89,91   
 
Noctural sleep disturbances 
Sleep disturbances in LBD can be severe and include insomnia, sleep fragmentation, REM sleep 
behaviour disorder (RBD), motor-related sleep disturbances, restless legs syndrome (RLS), periodic 
limb movements, obstructive sleep apnoea (OSA) and excessive daytime sleepiness.3  Most of the 
evidence base for the management of these comes from studies conducted in PD and idiopathic RBD 
rather than in LBD. Management begins with education on good sleep hygiene, and avoidance of any 
drugs that may affect sleep or alertness.8  
 
For insomnia, meta-analysis of melatonin from 9 randomised control trials across a range of 
neurodegenerative conditions such as PD (including a study of 40 patients) found improvements in 
subjective sleep quality although not objective measures and appears to be well tolerated.92,93  Z-
drugs (non-benzodiazepine) such as eszopiclone, zopiclone, or zolpidem, have no evidence base in 
LBD but expert consensus opinion suggested that they may be considered for short term treatment 
of insomnia if there is no evidence of sleep apnoea, with the caveat that they may have negative 
impacts on cognition, daytime sleepiness and increase the risk of fractures and falls.94 If sleep 
disturbances occur secondary to nocturnal parkinsonism, the use of long-acting levodopa 
preparations has been advocated.95 Randomised controlled studies have demonstrated that 
dopaminergic medications such as ropinirole, pramipexole, and rotigotine have efficacy in treating 
idiopathic RLS.95 but there is no clear evidence for the management of RLS in LBD. A meta-analysis of 
35 studies in 7333 participants with RLS found that gabapentin may be equally effective.96 However 
all of the above agents would need to be used with caution in LBD given their attendant cognitive 
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side effects (expert opinion). OSA may occur in up to a third of patients with LBD97 and is often 
unrecognised. Patients may experience excessive daytime somnolence, worsening cognitive 
function, unrefreshing sleep, and early morning headaches.98 Pauses in breathing whilst asleep and 
regular snoring raise the suspicion of this particular sleep symptom and there are a number of 
associated risk factors (overweight, male, smoker, on sedatives, alcohol use, reflux and anatomical 
considerations e.g. collar size >43 cm or 17 inches)99 which should be assessed for. 
  
RBD is a parasomnia manifested by recurrent dream enactment behaviour that includes movements 
mimicking dream content and associated with an absence of normal REM sleep atonia. Between half 
to three quarters of patients with LBD experience RBD100,101 and it is a core symptom for the 
diagnosis of DLB.3 It can antedate the onset of PD and LBD by many years or may emerge during the 
dementia phase.102,103 However it is important to recognise that obstructive sleep apnoea, 
narcolepsy, as well as nocturnal arousal events coupled with confusion may mimic RBD.97,103 
Determining the origin of sleep disturbance in LBD may therefore require polysomnography.3 Delphi 
consensus opinion  highlighted a number of non-pharmacological strategies which have been tried in 
RBD in LBD including, for example, lowering bed or placing mattress on the floor, removal of 
potentially dangerous objects in the bedroom such as sharp or glass objects, or if necessary, that bed 
partners to sleep separately from the patient. Some medications may worsen RBD (e.g. 
antidepressants)104 and in terms of active treatment, retrospective case series in idiopathic and 
secondary RBD support the use of clonazepam, though caution is needed in people with LBD who 
are more prone to gait disturbance, sleep apnoea, marked cognitive impairment and are at 
significant risk of falls (see105 for discussion). Pramipexole has been evaluated in observational 
studies as potentially effective for treating RBD in PD95 but is associated with an increased risk of 
psychosis.106 Melatonin (3 mg to 12 mg before bedtime), has a better side effect profile, and has an 
evidence base in the treatment of idiopathic RBD105,107. Another option is memantine; this agent 
decreased physical activity during sleep over 24 weeks in a controlled study of 20 LBD patients, while 
patients in the placebo group (n=22) worsened.108   
 
Excessive Daytime Sleepiness 
This is common in LBD109 and can make daily function challenging for patients and carers. 
Management is difficult and primarily draws upon ensuring good sleep hygiene and assessing for 
other potential causes or factors which might exacerbate the sleepiness.67. An open label trial of 20 
DLB patients with hypersomnia with armodafinil reported improvements in sleepiness, 
neuropsychiatric symptoms and carer quality of life.20  A trial of methylphenidate for gait 
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dysfunction in PD110,111 found improvements in excessive sleepiness as a secondary outcome, but 
there are no studies assessing sleepiness as a primary efficacy outcome measure in PD or LBD. Other 
treatments such as atomoxetine, sodium oxybate, istradefylline and caffeine have been investigated 
for sleepiness (in PD) but evidence to support their efficacy remains insufficient at present.112 In LBD 
memantine did not improve day time sleepiness in a small controlled trial of 42 patients.108  
 
In summary, extrapolating from the evidence base in PD and related disorders, management of sleep 
problems in LBD includes attention to sleep hygiene and the avoidance of exacerbating factors. RBD 
treatment may include clonazepam, melatonin, or potentially memantine. Management of OSA is 
best undertaken by specialist sleep services. Further studies of management strategies for specific 
sleep disturbances in DLB, including RBD and excessive daytime sleepiness are needed. 
 
Conclusions and future directions  
This review has summarised the evidence base for pharmacological and non-pharmacological 
management of LBD which can inform patient management.  It is important that treatment of any 
single symptom should not be done in isolation, as benefit in one domain may sometimes be gained 
at the cost of deterioration in another. A multi-specialist/ interdisciplinary approach is likely to 
produce greatest therapeutic gains, although delivery of that may present practical and logistical 
challenges for health care services.  
 
There are many areas which need further research (table 4)113 and a major unmet challenge is the 
relative paucity of evidence from high quality, large scale clinical trials in LBD. Given the 
heterogeneous nature of LBD and the different constellations of symptoms with which patients can 
present, trial design, and definition of outcome measures, remain problematic and need to be 
prioritised and agreed upon with the regulatory bodies before large trials are embarked upon. We 
also need to improve our understanding of the underlying molecular mechanisms and to identify 
novel targets for therapeutic intervention. Inclusion of LBD in formal diagnostic classifications such 
as DSM-5 and ICD-11 is a significant step forward as this is expected to drive interest in developing 
therapeutics for these conditions which are needed in equal measure across all of the symptom 
domains discussed above.  It appears that there already is an increase in trial activity in LBD (table 5). 
International strategic efforts such as European DLB consortium (E-DLB) and the US based LBD 
Research Centres of Excellence networks (https://www.lbda.org/rcoecenters) are also providing 
important research infrastructure to support such work and resources need to be directed into 
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developing and strengthening these. The scale of costs and unmet need in LBD is high, and although 
LBD management may be complex, the potential benefits are also substantial.  
 
Search strategy and selection criteria 
The full search and paper selection criteria for interventions in LBD are described in the Appendix.  In 
brief, clinical trials and intervention studies in LBD were identified as described in14 and 18 through 
bibliographic databases, trials registers, and gray literature. Search terms for identification of these 
studies included (Lewy OR Park*/parkinson) and dementia and we extended these searches from 
our original systematic reviews to 13th of February 2019. In these two systematic reviews, at least 
two reviewers independently assessed search results for inclusion by title and abstract with papers 
reviewed in full if participants had a diagnosis of DLB, PDD, or LBD (or were the caregivers of patients 
with these diagnoses) and were relevant. Reference lists of relevant studies and previous systematic 
reviews were also examined.  In addition, for the purposes of the present review we also sought 
input from members of the Delphi expert consensus panel (listed in Appendix) for any missing 
literature as well as relevant trials in AD and PD and papers pertinent to LBD symptom aetiology and 
epidemiology. We prioritised articles published in the past five years (from 1st January 2013) as well 
as systematic reviews and meta-analyses where these were available. Older articles for citation were 
chosen for their historical value, importance, ease of access, and timeliness. 
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Appendix 
Section I: Description of search methods 
The review was underpinned by two major systematic reviews conducted by the Diamond-Lewy study group 
focussing on pharmacological1 and non-pharmacological2 management strategies in Lewy body dementia 
(LBD). Details of the search strategy, study selection and data synthesis as described in Stinton et al.1 and 
Connor et al.2 are described below.   
Pharmacological management strategies1 
Search Strategy  
Studies were identified through bibliographic databases, trials registers, and gray literature (see the registered 
protocol for full details). Reference lists of relevant studies and previous systematic reviews were also 
examined, and input was sought from experts on Lewy body dementia. We used the keywords “Lewy or 
parkinson” and “dementia,” conducting searches until March 2015, without restrictions on time or language. 
Study Selection 
Titles and abstracts were screened independently by four of the authors, with non-English language papers 
screened by native speakers. Discrepancies were resolved through discussion between screeners. Potentially 
relevant studies were obtained in full and examined in detail by the first author against the following criteria: 1) 
participants had a diagnosis of DLB, PDD, or Lewy body dementia (or were the caregivers of patients with 
these diagnoses); 2) studies examined pharmacological strategies; and 3) outcome measures and scores were 
specified. No restrictions were placed on study design, but opinion papers were excluded.  
Data Extraction 
Data were extracted by two reviewers and recorded in an Excel spreadsheet. We collected information related to 
participant demographic characteristics, selection criteria, study design, management strategies, outcome 
measures and scores, adverse events, and withdrawals. 
Data Synthesis 
Studies were grouped and analyzed according to pharmacological strategy. For each strategy, studies of the 
highest level of evidence were included in the review. Classification of level of evidence was determined using 
guidelines from the Oxford Centre for Evidence-Based Medicine (https://www.cebm.net/2016/05/ocebm-levels-
of-evidence). 
Methodological Quality 
Methodological quality was assessed by three of the authors using the Quality Assessment Tool for Quantitative 
Studies (QATQS, www.ephpp.ca/tools.html)3, which was developed to assess quality across study designs, 
aiding consistency and clarity of reporting. The QATQS examines selection bias, study design, confounders, 
blinding, data collection methods, withdrawals, and dropouts. Domains are rated as being of weak, moderate, or 
strong quality, which feed into an overall rating of study quality. The reliability and validity of the QATQS have 
been demonstrated.4 
Statistical Analysis 
Meta-analysis was conducted using the Cochrane Collaboration’s RevMan, version 5.3 
(www.tech.cochrane.org/revman), employing the inverse variance method. Heterogeneity was assessed using 
the chi-square and I2 statistics and considered significant with p values <0.10 for chi-square and >40% for I2. 
We employed random-effects models when there was significant study heterogeneity and fixed-effect models 
when heterogeneity was not significant. Missing data were sought from study authors; for data that were not 
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obtainable, values were estimated using methods outlined in the Cochrane Handbook for Systematic Reviews of 
Interventions (www.cochrane-handbook.org). We estimated risk ratio with 95% confidence intervals for 
dichotomous outcomes and weighted mean difference or standardized mean difference with 95% confidence 
intervals for continuous outcomes. Descriptive summaries were provided when studies could not be combined. 
Non-pharmacological management strategies review2 
Search strategy 
The search identified studies through bibliographic databases, trial registers, and the grey literature. Bibliographic 
databases and trial registers included the following: Medline (1946–present); PreMedline, PubMed; EMBASE 
(1974–present), Scopus, Web of Science (1900–current); PsychInfo (1806–present); CINAHL (1981–present); 
Cochrane libraries: Cochrane database of systematic reviews (2005–October 2016), Cochrane central register of 
controlled trials (August 2016), Cochrane Methodology register (3rd–Quarter 2012); other EBM databases: ACP 
journal club (1991–September 2016), Database of Abstracts of Reviews of Effects (1st-quarter 2015), Health 
technology assessment (3rd-quarter 2016), and NHS economic evaluation (1st-quarter 2015); Ageline (1978–
present); ALOIS; AMED (Allied and Complementary Medicine; 1985–present); PEDro (Physiotherapy Evidence 
Database; 1929–present); Social work Abstracts (1968–present); and the National Association of Social Workers 
(NASW) clinical register (14th edition). The grey literature was searched using such resources as SIGLE (System 
for Information on Grey Literature in Europe), NTIS (National Technical Information Service) database, and 
PsychEXTRA (1908–present). 
The search strategy used only population and intervention terms to maximise the likelihood of identifying 
relevant studies (comparator and outcome terms were not used). The population was people with Lewy body 
dementia or their carers. This was identified using the search terms: [(Lewy OR Park*) and Dementia]. 
Interventions were any non-pharmacological treatment and identified using a wide range of terms: (activit*, 
acupuncture, alternative, animal, aromatherapy, art therapy, assisted, balance, behav*, bicycle, calisthenics, carer 
intervention, caregiver intervention, CBT, Chi gong, cognit*, cognitive behavioral therapy, cognitive behavioural 
therapy, counsel*, creative arts, dance, dancing, diet, direct current stimulation, drama, ECT, educat*, 
electroconvulsive therapy, enhanc*, environmental intervention, environmental modification, exercise, flexibility, 
humor therapy, humour therapy, hydrotherapy, intervention*, leisure, light therapy, management, martial arts, 
massage, meditation, Montessori, multisensory, music, non-pharm*, nonpharm*, nutrition, occupational therapy, 
pet therapy, physical activity, physical therapy, physiotherapy, pilates, psychoeducation, psychol*, psychosocial, 
psychotherapy, Qi gong, reality orientation, recreation*, reminiscence, resistance training, run*, sensory, 
simulated presence, stimulation, Snoezelen, support*, support group*, swim*, tai chi, therap*, therapeutic 
activity, TMS, training, training carers, training caregivers, transcranial magnetic stimulation, treatment*, 
validation, weight training, yoga). Searches were conducted on 30 October 2016. 
In addition to bibliographic database searches, the reference lists of papers included in the review and 
previous systematic reviews on both Lewy body dementia and non-pharmacological interventions were checked 
for relevant papers. Advice was also sought from experts in the field. 
Study selection 
Two reviewers independently assessed search results for inclusion by title and abstract. All articles deemed 
relevant by either reviewer were obtained in full. Both reviewers then independently evaluated full-text articles 
for inclusion. Any disagreements were resolved through discussion or, if necessary, with a third reviewer. 
Data extraction 
Two reviewers independently extracted relevant data from publications using a standardised form. This included 
participant details (e.g. demographics, number, recruitment, clinical context, dementia severity), intervention type, 
study design, measures, and results. Qualitative data were also collated. 
The primary outcomes were measures of cognition, function, neuropsychiatric symptoms, and motor 
symptoms. The secondary outcomes were measures of any other clinically relevant outcomes, such as quality of 
life, carer burden, financial costs, other symptoms (sleep or autonomic disturbances), and objective endpoints (e.g. 
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falls, hospitalisation, institutionalisation, mortality). Secondary outcomes also included the perceived 
acceptability of treatments, reported side effects, and dropout rates (a measure of treatment acceptability). 
Quality assessment 
Two reviewers independently assessed study quality and risk of bias using standardised tools. These included 
the Effective Public Health Practice Project Quality Assessment Tool for Quantitative Studies 
(http://www.ephpp.ca/tools.html)4 and the NICE Methodology Checklist: Qualitative Studies 
(https://www.nice.org.uk/process/pmg10/). Any disagreements were resolved through discussion. 
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Section II: Summary of expert consensus panel approach and method 
Structured expert consensus approaches such as the Delphi method can provide a complimentary framework to 
evidence based medicine for defining treatment approaches particularly in areas where there is an absence of 
high quality evidence.1,2 Typically the process is iterative, with expert feedback provided in successive rounds 
helping to refine previous statements of practise and best management. It also offers, particularly if administered 
electronically, advantages in incorporating multiple opinions and managing conflicting perspectives, whilst 
overcoming challenges of groupthink, as it is done individually and anonymously.2,3 
This Delphi expert consensus approach supported key statements in our review and also underpins the 
development of our management guideline and toolkits which are available online at 
https://research.ncl.ac.uk/diamondlewy/   
We took a process led approach: 
1) Establishment of the existing evidence base in LBD: as noted in Section I, formal systematic reviews 
and meta-analysis were conducted to capture all available, recent published information about the 
pharmacological and non-pharmacological management of LBD.4-5 
2) Public-patient workshops: Two public-patient workshops were held with participation of 38 people 
with LBD and their family/care-givers, with the first event focussing upon identifying best practice in 
LBD clinical management, based on their own experiences. The emergent themes were developed 
further in the second event and refined into a set of guiding principles. 
3) Using the systematic reviews and public-patient feedback an initial draft of the guidelines was 
developed by two authors (J-P.T and IGM). Specific statements, framed under symptom domains were 
created and submitted to an online anonymised online platform for review by our Delphi expert panel. 
The panel comprised experts in the field (n=26; psychology, geriatrics, psychiatry, neurology, primary 
care, physiotherapy, nursing, academic experts as well as internationally recognised key opinion 
leaders), identified through consultation with relevant stakeholder groups and supported by an 
extensive search of the literature for their publications, and/or the role as keynote speakers on 
management of LBD at major conferences. The Delphi process was conducted over three rounds. A 
high level of agreement was sought across the three rounds (85% for rounds 1 and 2 and 75% for round 
3). Controversial statements were modified on the basis of feedback and rerun in subsequent rounds or 
removed. Of 252 original statements, 161 were kept, with 78 of these (48.4%) gaining full consensus 
panel agreement for inclusion, 52(32.3%) with 90% to 99% consensus agreement and 31 statements 
(19.3%) agreed by 75% to 89% of the panel. After this process, the guideline statements were re-
collated and formulated into one document.  
4) Where there was an absence of evidence in our review, we draw upon the statements and the opinion of 
our Delphi expert group to inform best clinical practise. 
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